{"version":"1.0","type":"link","title":"Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Cohort Study.","author_name":"Taniki N 외","author_url":"https://prs-insight.online/author/Taniki%20N","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/112145","thumbnail_width":1200,"thumbnail_height":630}